The Upregulation of LAG-3 on T Cells Defines a Subpopulation with Functional Exhaustion and Correlates with Disease Progression in HIV-Infected Subjects

Xiaoling Tian, Anli Zhang, Chao Qiu, Wei Wang, Yu Yang, Chenli Qiu, Aiping Liu, Lingyan Zhu, Songhua Yuan, Huiliang Hu, Wanhai Wang, Qiang Wei, Xiaoyan Zhang and Jianqing Xu

*J Immunol* published online 16 March 2015
http://www.jimmunol.org/content/early/2015/03/14/jimmunol.1402176

Supplementary Material
http://www.jimmunol.org/content/suppl/2015/03/14/jimmunol.1402176.DCSupplemental

Subscription
Information about subscribing to *The Journal of Immunology* is online at:
http://jimmunol.org/subscription

Permissions
Submit copyright permission requests at:
http://www.aai.org/About/Publications/JI/copyright.html

Email Alerts
Receive free email-alerts when new articles cite this article. Sign up at:
http://jimmunol.org/alerts
The Upregulation of LAG-3 on T Cells Defines a Subpopulation with Functional Exhaustion and Correlates with Disease Progression in HIV-Infected Subjects

Xiaoling Tian,* Anli Zhang,* Chao Qiu,* Wei Wang, † Yu Yang,* Chenli Qiu,* Aiping Liu,* Lingyan Zhu,* Songhua Yuan,* Huiliang Hu,* Wanhai Wang,* Qing Wei, † Xiaoyan Zhang,* and Jianqing Xu*†

T cells develop functional defects during HIV-1 infection, partially due to the upregulation of inhibitory receptors such as programmed death-1 (PD-1) and CTLA-4. However, the role of lymphocyte activation gene-3 (LAG-3; CD223), also known as an inhibitory receptor, in HIV infection remains to be determined. In this study, we revealed that LAG-3 on T cells delivers an inhibitory signal to downregulate T cell functionality, thereby playing an immunoregulatory role during persistent HIV-1 infection. We observed that HIV-1 infection results in a significant increase in LAG-3 expression in both the peripheral blood and the lymph nodes. The upregulation of LAG-3 is dramatically manifested on both CD4+ and CD8+ T cells and is correlated with disease progression. As expected, prolonged antiretroviral therapy reduces the expression of LAG-3 on both CD4+ and CD8+ T cells. The ex vivo blockade of LAG-3 significantly augments HIV-specific CD4+ and CD8+ T cell responses, whereas the overexpression of LAG-3 in T cells or the stimulation of LAG-3 on T cells leads to the reduction of T cell responses. Furthermore, most LAG-3 and PD-1 are expressed in different T cell subsets. Taken together, these data demonstrate that the LAG-3/MHC class II pathway plays an immunoregulatory role, thereby providing an important target for enhancing immune reconstitution in HIV-infected patients. Additionally, the LAG-3/MHC class II pathway may synergize with PD-1/PD ligand to enhance T cell–mediated immune responses. The Journal of Immunology, 2015, 194: 000–000.

Human immunodeficiency virus–specific CD8+ T cells are known to play critical roles in the containment of HIV-1 replication (1–3). HIV-1 infection could result in a progressive impairment of HIV-specific CD8+ T cells, potentially causing functional exhaustion in the late stage of infection (4, 5); however, the mechanism underlying this observation remains elusive. It has been shown that HIV-specific CD8+ T cells are subjected to functional regulation by inhibitory molecules such as programmed death-1 (PD-1), CTLA-4, 2B4 (CD244), B and T lymphocyte attenuator, CD160, and Tim-3 (6–14).

Previous reports demonstrated that PD-1 was significantly upregulated on virus-specific CD8+ T cells and that CTLA-4 was upregulated on HIV-specific CD4+ T cells during persistent viral infection; both PD-1 and CTLA-4 could negatively regulate T cell functionality (6, 7, 15). Similarly to CTLA-4 and PD-1, lymphocyte activation gene-3 (LAG-3), which is a natural high-affinity ligand for MHC class II (MHC II) molecules (16), was shown to play an inhibitory role in regulating T cell immune responses by several studies (17–21). Accelerated autoimmune diabetes was documented in the absence of LAG-3 in NOD mice (22). LAG-3 acted synergistically with PD-1 to regulate T cell function (23), and the synergistic actions of these two molecules were critical for the prevention of autoimmunity in mice (24). In a murine transplantable tumor model, it was observed that PD-1 and LAG-3 were coexpressed on tumor-infiltrating CD4+ and CD8+ T cells (23). Plasmodium infection induced T cell exhaustion, which could be restored by the blockade of PD ligand 1 (PD-L1) and LAG-3 in vivo; blocking PD-L1 and LAG-3 restored CD4+ T cell function, amplified the numbers of follicular helper T cells, enhanced protective Abs, and rapidly cleared the established bloodstream Plasmodium infection in mice (25). LAG-3 also defines an active CD4+CD25highFoxp3+ regulatory T cell subset, the fre-
quency of which is enhanced in the PBMCs of cancer patients (26). There is increasing evidence of the role of LAG-3 and its involvement in regulatory T cell functions (27, 28).

However, less is known on the role and function of the LAG-3 pathway during HIV-1 infection in vivo. LAG-3 is expressed on activated CD4+ T and CD8+ T cells. After binding to its ligands, LAG-3 negatively regulates T cell signaling via interaction with the TCR “CD3 complex” (18–21) and controls the size of the memory T cell pool (29). Although chronic HIV persistent infection sig-

naling resulted in T cell functional exhaustion, the general under-

lying mechanism and the specific involvement of LAG-3, as an inhibitory molecule, in T cell depletion/njury in the peripheral blood in chronic HIV-1 infection remain largely unknown.

In this study, we measured LAG-3 expression in HIV-1–infected subjects and examined the association of LAG-3 with disease progression. We also assessed the effect of blocking LAG-3 ex vivo on T cells. Our data show that LAG-3 plays a regulatory role on both CD4+ and CD8+ T cells and is associated with disease pro-

gression during HIV-1 infection. These data could have important implications for targeting LAG-3 as a potential immune interven-
tion target to restore T cell function during HIV-1 infection.

Materials and Methods

Human study subjects

Fifty-four HIV-1–infected individuals were enrolled in our study. Human subject protocols were followed as previously described (30). The lower detection limit for HIV-1 RNA is 50 copies/ml. Twenty-five HIV-
eronegative subjects were recruited as healthy controls. The demographic information and clinical characteristics of the subjects are listed in Table I. Written informed consent was obtained from all participants. The overall study was reviewed and approved by the Ethics Committee of the Shanghai Public Health Clinical Centre to ensure the protection of human subjects.

Cell isolation and phenotypic analysis

Human and rhesus macaque PBMCs were isolated from freshly heparinized blood. To characterize the phenotypes of LAG-3+CD4+ or CD8+ T cells, PBMCs were stained with Pacific Blue–conjugated anti-human CD3 Ab (clone UCHT1; BD Biosciences), PerCP-Cy5.5–conjugated anti-human CD4 (clone SK3; BD Biosciences), allophycocyanin-H7–conjugated anti-human CD8 (clone RPA-T8; eBioscience), FITC–conjugated anti-human CD19 (clone HIB19; eBioscience), allophycocyanin-conjugated anti-

human PD-1 (clone EH12.2H7; BioLegend), Pacific Blue–conjugated anti-human CD95 (clone DX2; eBioscience), PE-Cy7–conjugated anti-human CD45RA (clone HI100; eBioscience), allophycocyanin-conjugated anti-human CCR7 (clone 3D12; eBioscience), PE-Cy7–conjugated anti-human LAG-3, and allophycocyanin-conjugated anti-human LAG-3 (polyclonal Ab; R&D Systems) Abs. HIV-1 Gag–SLYNTVATL– and Pol–ILKEPVHGV– specific CD8+ T cells were identified using HLA-A*0201 tetramers, and HIV-1 Env–RYLLKDQLQ– and Neo–RYLPITFGWCY–specific CD8+ T cells were identified using HLA-A*2402 tetramers (QuantumBio). The Live/Dead blue dye (Invitrogen) was used to exclude dead cells. The cells were then washed and fixed in PBS plus 1% paraformaldehyde. A total of >200,000 events were collected and analyzed using a FACS caliber flow cytometer (Becton Dickinson) and FlowJo 7.6 software.

Ex vivo Ab blockade

PBMCs were treated with anti-human CD274 (B7-H1) Abs, also known as anti-human PD-L1 (clone MIH1; eBioscience) (2 μg/ml), or IgG1 isotype control (eBioscience) (2 μg/ml), in combination with human LAG-3–Fc chimera (R&D Systems) (2 μg/ml) in the presence of overlapping HIV-1 clade B Gag pooled peptides (B Gag) (2.5 μg/ml, National Institutes of Health AIDS Research and Reference Reagent) or CMV/EBV/influenza virus (CEF) pooled peptides (AnaSpec) (2.5 μg/ml). Staphylococcal enterotoxin B (SEB; Sigma-Aldrich) (0.5 μg/ml) was used as positive control. After 24 h of incubation, the cytokines IL-2, IL-10, and TNF-α were measured by flow cytometry with the cytokometric bead array (CBA) human Th1/Th2/Th17 cytokine kit (BD Biosciences) by following the manufacturer’s protocol; IFN-γ was measured using an ELISPOT assay (BD Biosciences). After fixation and permeabilization (Fix/Perm kit; BD Biosciences), intracellular cytokine staining (ICS) was performed with allophycocyanin-conjugated anti-human IFN-γ (clone 4S.B3; BioLegend) and the corresponding Abs against surface markers.

Proliferation assay

To track cell division, PBMCs from chronically HIV-1–infected individuals were labeled with 5 μM cell proliferation dye eFluor 670 (eBioscience) in PBS and incubated for 10 min at 37°C. Labeling was quenched by the addition of five volumes of cold complete media (10% FBS in RPMI 1640) on ice for 5 min. The labeled cells were then washed twice and resus-

pended in RPMI 1640 (Life Technologies). Cell proliferation dye eFluor 670–labeled cells were then stimulated for 6 d in the presence of HIV-1 B Gag peptides or SEB plus recombinant human IL-2 (50 IU/ml) (R&D Systems), 2 μg/ml IgG, or anti-human PD-L1 or LAG-3 Fc and replen-

shed every 2 d. The cultures were restimulated after 6 d, and cell pro-
liferation was measured on day 7.

Semi-quantitative real-time PCR

Total RNA was extracted from peripheral blood of the subjects using the Qiagen blood RNA kit (Qiagen) following the manufacturer’s protocol, and then transcribed into cDNA using oligo(dT) with Moloney murine leukemia virus (Invitrogen). The quantitative expressions of LAG-3 tran-

scripts were subsequently determined using SYBR Green real-time PCR master mixes (Invitrogen). The sets of primers were designed for the quantitative PCR with the primer design software Primer Premier 5.0. The sequences of the forward and reverse primers for LAG-3 mRNA are 5’-TCATCTTCTGTGGCTTCAGAG-3’ and 5’-GTTAAAGTCGCCATTGT- CTC-3’, respectively. For GAPDH mRNA, the forward and reverse primers are 5’-AATTGGGCAACCGTATTGAAA-3’ and 5’-GCCCATATACCAGC- AAATCAGAG-3’, respectively. The reaction conditions were as follows: 95°C for 2 min, followed by 40 cycles of 95°C for 15 s, 60°C for 15 s, and 68°C for 25 s. A final dissociation step was run to generate a melting curve to verify the specificity of the amplification product. Quantification of the target gene expression was performed using the 2–ΔΔCt method according to the manufacturer’s instructions (Applied Biosystems).

Generation of LAG-3 and the hLAG-3-IC/mCD28 chimeric gene

LAG-3 was cloned by RT-PCR, and the chimeric gene was generated by fusing the intracellular domain (IC) of LAG-3 to the extracellular and transmembrane domains of murine (m)CD28 (designated as hlag-3-IC/ mCD28). All genes were confirmed by PCR and sequencing. Both genes were inserted into the transferring plasmid pCLPs.

Production of high-titer lentiviral vectors and transduction into Jurkat cells

Lentiviral vectors were produced after the transfection of 293T human embryonic kidney cells with three plasmids; for sorting, this system encodes an enhanced GFP (eGFP) protein or mCD28. Cells were transfected with VSV-G (envelope), pSAX (packaging plasmid), and pWPI (transfer plasmid) or pCLP (transfer plasmid) using the TurboFect transfection reagent (Thermo Scientific; R0531). High-glucose DMEM was replenished 6 h af-

ter transfection, and the viral supernatant was harvested at 48 h post-

transfection. Subsequently, 250 μl lentivirus was incubated with Jurkat cells and DEAEx-dextran (15 μg/ml) on 24-well plates at 37°C. On the following day, the medium was exchanged and the cells were expanded. After 48 h, LAG-3 gene expression was examined and eGFP or mCD28 cells were sorted by flow cytometry. The cells were then passaged for further screening to identify the stable expression of eGFP alone (vector control) or in combination with LAG-3 or mCD28.

Plasmid DNA nucleofection of CD8+ T cells

CD8+ T cells of HIV-infected individuals were purified using magnetic negative selection for CD8+ T cells, following the manufacturer’s proto-
cols (StemCell Technologies). The plasmid DNA pWPI or pWPILAG-3 was transfected into purified CD8+ T cells using the Nucleofector II device (Amaxa) and Amaxa T cell transfection reagents (Lonza) according to the manufacturer’s directions. CD8+ T cells were nucleofected with either pWPI or pWPI-LAG-3 using the Nucleofector II device (program U014) and Amaxa human T cell transfection reagents (Lonza). Forty-eight hours after nucleofection, the cells were incubated with HIV-1 B Gag pooled peptides, and ICS was performed with anti-human IFN-γ and corre-
sponding Abs against surface markers.

Immunohistochemistry

Histological analyses were performed on formalin-fixed, paraffin-

embedded tissues. Lymph node samples were obtained from the Depart-
ment of Pathology at Shanghai Public Health Clinical Centre. Human
lymphoid tissue (formalin-fixed, paraffin-embedded) was stained with mouse anti-human LAG-3 (clone 17B4; LifeSpan BioScience) Abs (5 μg/ml), followed by the EnVision G|2 Doublestain System, rabbit/mouse (diaminobenzidine+/permanent red) (DakoCytomation), according to the manufacturer’s instructions. Representative images showing LAG-3 immunohistochemical staining were generated using custom software from Tissue Gnostics (HistoQuest 3.0.3.0148). All slides were digitally scanned at 320 magnification with use of a ScanScope CS slide scanner (Olympus CKX41).
Animals

Chinese-original rhesus macaques (Macaca mulatta), aged 4–6 y, were housed in biosafety level 3 containment facilities at the Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Peking Union Medical College and were maintained in accordance with the standards of the Association for Assessment and Accreditation of Laboratory Animal Care International. Animal experiments were approved by the Institutional Animal Care and Use Committee of Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and were conducted according to the principles described in the Guide for the Care and Use of Laboratory Animals of the Institute of Laboratory Animal Science (from 2006) and the use of nonhuman primates in research of the Institute of Laboratory Animal Science (from 2006). All of the animals selected for this study were negative for simian retrovirus type D, SIV, simian T lymphotropic virus type 1, simian herpesvirus B, tuberculosis, and parasites (e.g., Endamoeba), in accordance with national regulations (GB14922-2001).

All 25 macaques were anesthetized with ketamine hydrochloride or compound ketamine (10 mg/kg) injected i.m. and were i.v. (GB14922-2001).

Statistical analysis

All data were analyzed using the FlowJo 7.6 software. Significant differences between two groups were assessed by the Mann–Whitney non-parametric test. Data from the same individuals were compared by the Wilcoxon matched-pairs t test. Correlations between variables were calculated using a Spearman rank correlation test. For all tests, a p value < 0.05 was considered statistically significant.

Accession codes

Microarray data were from Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/) under accession no. GSE56837.

Results

LAG-3 expression in lymphocytes was significantly upregulated in HIV-1–infected subjects

The upregulation of LAG-3 was demonstrated in a previous study on tumor-infiltrating CD8+ T cells (31). Using a microarray, we profiled LAG-3 expression on PBMCs from a cohort of chronically HIV-1–infected and seronegative subjects. The upregulation of LAG-3 was observed in HIV-1–infected individuals compared with HIV-seronegative subjects (data not shown). To confirm the microarray data, we quantified LAG-3 mRNA by real-time PCR in 7 uninfected and 27 HIV-1–infected subjects naive to anti-retroviral therapy (ART). The results showed that LAG-3 expression (normalized to GAPDH) was significantly higher in HIV-1–infected subjects compared with uninfected subjects (p < 0.01) (Fig. 1A).

We then quantified LAG-3 expression on CD4+ and CD8+ T cells by flow cytometry in uninfected and chronically HIV-1–infected subjects naive to ART (Table I). The expression of LAG-3 in HIV-infected individuals was dramatically elevated on both CD4+ (p < 0.001) and CD8+ T cells (p = 0.046) compared with the HIV-seronegative group (Fig. 1B), and patients with higher proportions of LAG-3+ cells tended to have higher viral loads (>2000 copies/ml, labeled by a red circle) than those with lower proportions of LAG-3+ T cells (labeled by a blue circle) (Fig. 1B). We also measured the expression of LAG-3 in acutely SIV-infected Chinese rhesus monkeys; similarly, higher levels of LAG-3 were observed on CD3+CD8+ (p < 0.001) and CD3+CD8+ T cells (p < 0.001) in acutely SIV-infected rhesus monkeys compared with uninfected rhesus monkeys (Supplemental Fig. 1A).

We further investigated the expression of LAG-3 on lymphocytes of the lymph node, which is the primary site of HIV replication (32, 33), using paraffin-embedded tissue sections. Slide sections were derived from five HIV+ or three HIV+ lymph nodes (Fig. 1C). As shown in two representative images (left panel), extensive LAG-3 staining was observed in the lymphoid follicle, superficial cortex, and the inter cortex adjacent to the lymphoid follicle around and the medulla on the lymph node section from the HIV+ subject but not the HIV− subject. After all images were digitized, both the number of LAG-3–expressing cells and the signal density of LAG-3 were significantly increased in HIV+ subjects compared with HIV− individuals (p < 0.05) (middle and right panels).

LAG-3 expression correlates with disease progression

To assess whether the expression of LAG-3 was associated with HIV disease progression, we assessed the relationship between the overall LAG-3 mRNA expression and LAG-3 expression on CD4+ and CD8+ T cells by assessing CD4+ T cell counts and HIV plasma viral loads. As shown in Fig. 1D (left panel), LAG-3 mRNA expression, quantified by real-time PCR from 27 HIV-1–infected individuals, was significantly inversely correlated to the absolute CD4+ T cell counts (p = −0.46, p = 0.01) and positively correlated with the viral load (p = 0.55, p < 0.01). Similar correlations were observed between LAG-3 expression on CD4+ T cells and CD4+ T cell counts (p < 0.001) and the viral load (p = 0.03, middle panel), as well as between LAG-3 expression on CD8+ T cells and CD4+ T cell counts (p < 0.05, right panel). Our result shows that no significant association was identified between LAG-3 expression on CD8+ T cells and the viral load, whereas others reported that LAG-3 expression on HIV-specific CD8+ T cells was negatively correlated with the plasma viral load (34).

To test the association of LAG-3 expression with HIV-1 progression, patients were stratified into two groups with either high or low LAG-3 expression. Both the CD4+ T cell counts and viral loads between these two groups did not reach significant differences at the starting point (p = 0.76 for CD4 counts; p = 0.07 for viral loads) (Supplemental Fig. 1B). Interestingly, the patients with high LAG-3 expression had a much more significant effect on

Table I. Demographic and clinical characteristics of subjects

<table>
<thead>
<tr>
<th>HIV-1 Uninfected (HIV−)</th>
<th>ART−</th>
<th>ART+</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subject no.</td>
<td>25</td>
<td>54</td>
</tr>
<tr>
<td>Age (y)*</td>
<td>30 (25–45)</td>
<td>48 (33–64)</td>
</tr>
<tr>
<td>Male</td>
<td>16</td>
<td>41</td>
</tr>
<tr>
<td>Female</td>
<td>9</td>
<td>13</td>
</tr>
<tr>
<td>CD4 counts (cells/μl)*</td>
<td>N/A</td>
<td>365 (37–865)</td>
</tr>
<tr>
<td>Plasma HIV-1 load (copies/ml)*</td>
<td>N/A</td>
<td>3,600 (100–260,000)</td>
</tr>
</tbody>
</table>

The time on ART ranged from 1 to 6 years.

*Median (range).

LDL, lowest detection limit; N/A, not applicable.
the progression of HIV-1; 50% of patients reached the endpoint, whereas only ~10% patients with low LAG-3 expression reached the endpoint during a 2-y follow-up (Fig. 1E). These findings suggest that LAG-3 is likely involved in HIV-1 pathogenesis and that LAG-3 expression may be a new predictor for HIV-1 progression and survival.

LAG-3 was largely upregulated on activated and fully differentiated T cells

To assess the LAG-3–expressing T cell subsets, LAG-3 expression was analyzed in relationship to CD38 and HLA-DR, which are phenotypic markers associated with T cell activation. To characterize whether LAG-3 is coexpressed with other inhibitory or apoptosis-related molecules, we also performed dual staining for LAG-3 and PD-1 or CD95 on both CD4+ and CD8+ T cells. As shown in Fig. 2A, LAG-3+ cells were largely coexpressed with CD38 on 70 ± 9% of CD4+ T cells and 74 ± 17% of CD8+ T cells from 28 HIV-1–infected individuals; the percentage of cells coexpressing LAG-3 with HLA-DR was less, and those with PD-1 and CD95 were much less. These data indicated that LAG-3 was related to continuous T cell activation.

We next assessed the distribution of LAG-3 within the different CD4+ and CD8+ T cell subsets in HIV-1–infected individuals. LAG-3 was coexpressed with CD45RA, as well as with CCR7 to a much lower extent (Fig. 2B, Supplemental Fig. 2A) and defined fully differentiated subsets of CD4+ or CD8+ T cells (effector memory T [TEM] or terminal effector memory T [TEMRA] cells, respectively), which mediated the immediate effector function to induce Ag stimulation. Interestingly, PD-1 was more dominantly expressed on TEM cells for both CD4+ and CD8+ T cells, in agreement with a previous report (35).

To examine when LAG-3 is upregulated during activation, we kinetically monitored LAG-3 expression on T cells during anti-CD3/anti-CD28 stimulation in vitro. LAG-3 upregulation in response to anti-CD3/anti-CD28 was observed as early as 24 h after stimulation and progressively increased for at least up to 48 h, followed by a decrease to baseline levels (Supplemental Fig. 2B). Interestingly, most LAG-3+ T cells coexpressed PD-1 during the early activation phase. Only a small fraction of T cells expressed LAG-3 alone, and this fraction displayed different kinetics, with the LAG-3–expressing peak appearing on day 1 (Supplemental Fig. 2C). These data suggest that LAG-3 could be transiently upregulated in response to TCR stimulation. We speculate that the persistent upregulation of LAG-3 during HIV infection might reflect the persistent immune activation of T cells in response to the viral infection.

Prolonged ART downregulates the expression of LAG-3

To assess whether effective ART could reduce the elevated LAG-3 expression, longitudinal analysis of the effect of ART on LAG-3 expression in chronic HIV-1 infection was performed. As expected, after prolonged ART (>1 y), LAG-3 expression on both CD4+ and CD8+ T cells significantly declined in the mean fluorescence intensity (MFI) and frequencies of LAG-3+ populations (Fig. 3A). The reduction of LAG-3 expression coincided with the increase in CD4+ T cell counts, as exemplified in two subjects (Fig. 3B).

The blockade of LAG-3 enhances HIV-specific T cell responses

We next tested whether the blockade of LAG-3 with its ligands could enhance HIV-specific T cell responses. A recombinant human LAG-3–Fc chimera was used to compete for LAG-3 ligands and to thus block the interaction of LAG-3 with its MHC II ligands during ex vivo stimulation for 24 h. PBMCs from clade B HIV-1–infected subjects naive to ART were incubated with B Gag or CEP peptide pool as controls in the presence of LAG-3–Fc, anti–PD-L1 or isotype control Igs. As shown in Fig. 4A, after B Gag stimulation, the blockade of LAG-3 by LAG-3–Fc fusion proteins significantly enhanced both CD4+ and CD8+ IFN-γ responses compared with the isotype control (p < 0.01 for both) in an IFN-γ–based ICS assay on PBMCs from nine HIV-infected subjects. Stimulation without Gag or with SEB was employed as
a negative or positive control, respectively. Interestingly, the blockade by anti–PD-L1 Abs also resulted in an increase in both CD4+ and CD8+ IFN-γ responses compared with the isotype control (p = 0.01 and p < 0.01, respectively). In parallel, the IFN-γ–based ELISPOT assay revealed similar results for LAG-3–Fc- and anti–PD-L1-mediated blockages. In contrast, no significant increase was identified for either LAG-3–Fc- or anti–PD-L1-mediated blockage after CEF peptide pool stimulation (Fig. 4B), indicating that LAG-3–mediated suppression mainly occurs in T cells against an ongoing persistent HIV infection.

We next examined whether LAG-3 blockade could also enhance the Ag-specific proliferative capacity of T cells in vitro. PBMCs were labeled with the cell proliferation dye eFluor 670 (eBioscience, 5 µM), incubated with LAG-3–Fc or isotype control Abs plus exogenous IL-2 (50 IU/ml) in the presence of Gag peptides, and analyzed by flow cytometry after 6 d. We showed that LAG-3 blockade resulted in an increase in HIV-specific IFN-γ+CD8+ T (Fig. 4C) and IFN-γ+CD4+ T cell proliferation (Supplemental Fig. 3) in response to Gag stimulation. Furthermore, when a CBA assay was used to quantify the cytokines IL-2, TNF-α, and IL-10 in the supernatants, significant increases were observed after the blockade by LAG-3–Fc or anti–PD-L1 Abs (Fig. 4D).

To understand the reasons for the varied enhancing effects of LAG-3–Fc in different subjects and for the observed discrepancies between the blockade of the LAG-3 and PD-1 pathways, we examined LAG-3 and PD-1 expression on HIV-specific CD4+ and CD8+ T cells. Interestingly, HIV-1 Gag-specific CD4+ and CD8+ T cells from different subjects showed varied levels of LAG-3 expression (mean of 20%, ranging from 7.4 to 54%). Most LAG-3 and PD-1 were distributed on different HIV-specific T cell subsets, and only a small fraction of HIV-specific T cells coexpressed both LAG-3 and PD-1 (mean of 5%, ranging from 0.2 to 15.7%) (Fig. 4E). To rule out the potential influence of TCR stimulation on LAG-3 and PD-1 expression, we examined LAG-3 and PD-1 on HIV-1 Gag-A*0201 SL9–specific CD8+ T cells after tetramer staining in the absence of TCR stimulation, and a similar expression pattern was revealed for LAG-3 and PD-1 (Fig. 4F).

These data explain the varied effect of the LAG-3–Fc-mediated blockade on the enhancement of T cell immune responses in different HIV-infected subjects, suggesting that LAG-3–Fc and anti–PD-L1 predominantly targeted different T cell subsets.

Overall, these data demonstrate that the blockade of the LAG-3/MHC II pathway could enhance HIV-1–specific T cell responses ex vivo and that the LAG-3/MHC II pathway plays an important role in regulating HIV-specific T cell responses during persistent HIV-1 infection. Furthermore, the LAG-3/MHC II pathway could synergize with PD-1/PD-L1 to enhance T cell–mediated immune responses.

**LAG-3 delivers a regulatory signal to T cell responses**

To further confirm the role of LAG-3 on T cells, we overexpressed LAG-3 in Jurkat T cells and observed a decrease in IL-2 production in LAG-3–transfected Jurkat T cells compared with sham vector–transfected Jurkat T cells after stimulation with anti-CD3/anti-CD28 Abs (Fig. 5A). To enable functional studies of LAG-3 in primary human T lymphocytes, LAG-3 and the sham vector plasmid were transfected into purified CD8+ T cells. Importantly, when expressed in CD8+ T lymphocytes, LAG-3 was able to reduce IFN-γ production following Gag stimulation compared with the sham vector (Fig. 5B). To further assess whether LAG-3 transduces inhibitory signals, we constructed a fusion gene by fusing the cytoplasmic domain of LAG-3 to the outer membrane fragment of mouse CD28 (designated as hLAG-3-IC/mCD28), which enables the stimulation of LAG-3 via anti-mCD28 Abs. As shown in Fig. 5C, stimulation with anti-mCD28 Abs in addition to anti-hCD3 and anti-hCD28 Abs resulted in the reduction of IL-2 in hLAG-3-IC/mCD28–transfected Jurkat cells. These data demonstrated that LAG-3 transduces an inhibitory signal through its cytoplasmic domain.

**Discussion**

LAG-3 is a CD4 homolog that is required for the regulation of T cell activation, for the maximal function of regulatory T cells, and...
FIGURE 4. Blockade of LAG-3 enhanced T cell responses. (A) The blockade of LAG-3 increases the fraction of CD4+ and CD8+ T cells responding to HIV-1 B Gag stimulation. Representative flow cytometry plots show cytokine (IFN-γ) responses to HIV-1 B Gag peptides in the presence of IgG, LAG-3–Fc, or anti–PD-L1 Abs in CD4+ and CD8+ T cells or SEB alone (left panel). Compiled flow cytometry data from 14 chronically HIV-1–infected progressors are shown in the right panel. (B) The blockade of LAG-3 increases spot numbers in CD4+ and CD8+ T cells responding to HIV-1 B Gag stimulation. An ELISPOT assay was performed. Compiled data are shown for HIV-1 B Gag stimulation (n = 14) (upper panel) and CEF peptide stimulation (n = 9) (bottom panel), as well as for the comparison between IgG and LAG-3–Fc (left panel) and for the comparison between IgG and anti–PD-L1 Abs (right panel). (C) The blockade of LAG-3 improves HIV-specific CD8+ T cell proliferation. Representative data show the expansion of CD8+ T cells in response to stimulation with SEB or of HIV-1 B Gag peptides alone or in the presence of IgG, LAG-3–Fc, or anti–PD-L1 Abs. Compiled data from nine subjects were compared between IgG and LAG-3–Fc and between IgG and anti–PD-L1 Abs. Statistical comparisons are conducted using a Wilcoxon signed rank test. (D) The blockade of LAG-3 increases IL-2, IL-10, and TNF-α production. Supernatants were collected from the experiments above (C) and the cytokines IL-2, IL-10, and TNF-α were quantified by using a CBA assay. Compiled CBA data (n = 8) are shown for the comparison between IgG and LAG-3–Fc (upper panel) and between IgG and anti–PD-L1 Abs (bottom panel). The p values are calculated using the Wilcoxon signed rank test. (E) LAG-3 and PD-1 express on different HIV-1–specific IFN-γ+ CD4+ and CD8+ T cell subsets. HIV-1–specific CD4+ and CD8+ T cells are defined as IFN-γ+ T cells after HIV-1 Gag–derived peptide stimulation. One example of LAG-3 and PD-1 staining in IFN-γ+ CD4+ and CD8+ T cells is shown in the upper left panel, and the percentages of LAG-3 single-positive, PD-1 single-positive, and LAG-3/PD-1 double-positive CD4+ (upper) and CD8+ (bottom) T cells are shown in the right panel; the weight for each population of IFN-γ+ CD4+ and CD8+ T cells is shown in the bottom left panel (n = 8). (F) LAG-3 and PD-1 are expressed on HIV-1 Gag-A*0201 SL9 tetramer+ T cells. HIV-1–specific CD8+ T cells are defined as HIV-1 Gag-A*0201 SL9 tetramer staining–positive T cells in the absence of stimulation. The gating strategy is illustrated in the upper and bottom left panels, and four examples of LAG-3 and (Figure legend continues)
for the control of CD4+ and CD8+ T cell homeostasis (18–21, 29, 36). The interaction between LAG-3 on T cells and MHC II molecules on APCs delivers a negative signal to downregulate T cell proliferative and cytotoxic activities, thereby restraining the overexpansion of activated T cells and preventing the self-killing of APCs (17, 19, 21, 37). Meanwhile, this interaction also imparts a positive signal to APCs and promotes the maturation of APCs (38, 39), which enables APCs to raise more Ag-specific T cells. Therefore, the LAG-3/MHC II pathway may serve as an “amplifier” for the initiation of immune responses. In this context, the upregulation of LAG-3 on T cells after stimulation represents the “initiator” for the subsequent interaction between LAG-3 and MHC II. In agreement with this hypothesis, we observed the immediate upregulation of LAG-3 upon stimulation, which peaked at days 2–4 in our study, highlighting the important role of LAG-3 during the initiation of Ag-specific T cell–mediated immune responses. Notably, this mechanism would allow the immune system to maximize its usage of APCs to recruit T cells carrying corresponding Ag-specific TCRs, culminating in immune responses within a relatively short period of time.

As is known, activated T cells also express MHC II molecules (40, 41), which in turn may bind to LAG-3 on the same T cells and control their activities after those T cells are activated by APCs (21, 29, 42); this is particularly important when those activated T cells contact somatic cells carrying MHC class I (MHC I) but not MHC II molecules and screen for pathogen-derived epitopes in the context of MHC I complexes. The self-carrying MHC II molecules on T cells may generate a threshold for the initiation of activated T cell–mediated killing, preventing the occurrence of autoimmune activities when no pathogen-derived epitopes are present in the binding groove of MHC I molecules. In accordance with this hypothesis, knocking out LAG-3 could cause accelerated and aggravated autoimmune disease (22). In contrast, the presence of pathogen-derived epitopes in the complex of MHC I molecules could result in the high-affinity binding of MHC I/epitope and TCR, thereby transducing an enhanced signal to invoke the killing and elimination of pathogen-infected somatic cells.

This mechanism might be hijacked during HIV infection. HIV infection results in persistent viremia, and HIV-derived RNA/DNA and proteins continuously stimulate the innate immune cells and HIV-specific T cells, thereby generating an inflammatory environment and causing the persistent activation of HIV-specific T cells (43, 44). As shown in our data, the stimulation could result in the upregulation of LAG-3; it is possible that the persistent stimulation by both HIV Ags and inflammatory cytokines could result in the extensive upregulation of LAG-3, as evidenced in our

---

**FIGURE 5.** LAG-3 inhibits T cell function. (A) The transfection of Jurkat T cells with the lag-3 gene reduces IL-2 production in response to anti-CD3/anti-CD28 Ab stimulation. Flow cytometric plots show IL-2 production from unstimulated Jurkat T cells or from anti-CD3/anti-CD28–stimulated vector-transfected or lag-3–transfected Jurkat T cells (upper panel). Compiled data from three independent experiments are shown as percentages (left) or the MFI (right) in the bottom panel. (B) LAG-3 reduced IFN-γ in primary CD8+ T cells of HIV–infected individuals. Primary CD8+ T cells from PBMCs of HIV-1–infected patients were electroporated with plasmid DNA to express LAG-3 in relationship to GFP; 48 h later, CD8+ T cells were added back to PBMCs that were removed of CD3+ T cells and assessed for IFN-γ responses to HIV-1 B Gag peptides by flow cytometry. Representative data from five independent assays are shown in the upper panel, and pooled data from all five experiments are shown in the bottom panel. (C) The intracellular domain of LAG-3 inhibits IL-2 production in response to anti-CD3 and anti-CD28 Ab stimulation. The intracellular domain of LAG-3 was fused with the extracellular domain of mouse CD28, and this chimeric gene was electroporated into Jurkat T cells. Flow cytometric plots show IL-2 production after the stimulation of hlag-3-IC/mcd28–transfected Jurkat T cells with either anti-CD3/anti-CD28 or anti-CD3/anti-CD28/anti-mCD28. Compiled data from three independent experiments are shown.

---

PD-1 staining in tetramer+ CD8+ T cells are shown in the upper panel; the percentages of LAG-3 single-positive, PD-1 single-positive, and double-positive CD8+ T cells in HIV-1 Gag-A*0201 SL9 tetramer+ CD8+ T cells are shown in the bottom right panel (n = 14).
primate model of acute SIV infection. Because the lymph node is the primary site for HIV infection (32, 33), it is not surprising that in our study, lymph nodes from HIV-infected subjects showed highly extensive staining of LAG-3, indicating that LAG-3 was more widely expressed during HIV infection in lymph tissues, with the increased number of LAG-3–expressing T cells in the peripheral blood reflecting the events occurring in lymphatic tissues. The containment of HIV replication by ART could decrease LAG-3 expression, as shown in our data.

The extensive expression of LAG-3 might have two consequences. The first consequence is the severe attenuation of the immune capacity to contain HIV replication. As known, both CD4+ and CD8+ T cell responses are required to effectively suppress HIV replication (45, 46). Because LAG-3 transduces a negative regulatory signal into T cells, the upregulation of LAG-3 likely impairs T cell functionalities, as demonstrated by both the ELISPOT and ICS assays in this study, and thereby attenuated immune capacity to contain HIV replication. Therefore, the increased LAG-3 expression is likely to correlate with disease progression during HIV infection; this was corroborated by the reverse association with CD4+ T cell counts and the positive association with the viral load in our data. Blockage of the LAG-3 pathway by LAG-3–Fc fusion proteins significantly increased T cell responses, as quantified by IFN-γ–based assays, suggesting that the LAG-3–mediated impairment of T cell functionalities was at least partially reversible and could be recovered by interrupting the LAG-3/MHC II pathway. In this regard, LAG-3, similarly to PD-1 (6, 7, 47), could be considered as a T cell functional regulatory receptor and, as shown in this study, is mainly expressed on effector T cells. The second consequence is enhancement of the threshold to initiate fresh T cell responses. Because LAG-3 transduces a negative regulatory signal into T cells, the extensive expression of LAG-3 on T cells indicated the existence of “bystanding” upregulation of LAG-3 and might lead to a great challenge to raise fresh T cell responses because all dendritic cells, which are the primary APCs for the initiation of T cell responses (48), express high levels of MHC II molecules (49). Under this circumstance, the immune system may fail to initiate a fresh T cell response against a less immunogenic mutated HIV epitope or may require a prolonged period of time to tackle an immunogenic mutant HIV epitope. Similarly, an HIV-infected individual is likely to have difficulty fighting off a subsequent coinfection (47).

As previously reported, PD-1 was mainly upregulated in TEM cells (35), whereas LAG-3 was largely expressed on T EMRA and TEM cells. To understand how LAG-3 and PD-1 are coordinated during a persistent HIV infection, we assessed the coexpression of those two molecules. Surprisingly, only a small fraction of T cells coexpressed LAG-3 and PD-1, suggesting that they may play different roles, although both are upregulated during HIV infection and are considered as regulatory molecules. Additionally, PD-1 was shown to associate with both CD38 and HLA-DR (50), whereas LAG-3 coexpressed with CD38, as well as with HLA-DR and CD95 to a much lower extent, further indicating that PD-1 and LAG-3 represent two different functionally impaired T cell populations. Whether these different functionally impaired T cell populations were derived from different lymphatic tissues/sites or represented the same T cell population at different stages during functional exhaustion remains unknown.

Overall, we found that LAG-3 expression was significantly more extensive in HIV-infected subjects compared with uninfected individuals. The increased expression of LAG-3 was associated with disease progression and T cell functional impairment. LAG-3 transduces an inhibitory signal into T cells; thus, blocking LAG-3/CD95 interactions ex vivo could, at least in part, revitalize HIV-specific CD8+ T cell functions. LAG-3 and PD-1 represented two different damaged T cell populations. These findings not only extend our understanding of the mechanism of T cell functional exhaustion but also provide a potential therapeutic strategy for HIV-infected patients.

Acknowledgments
We thank the study participants for donating their blood for this study. We also thank Jun Xu for flow cytometry support. Thanks also go to the following people for assistance in coordinating patients for sample collection: Ximing Shi, Jinsheng Wang, Jun Wei, Shaohuan Jia, Shaoping Ning, and Xiujie Lu Yuncheng (Municipal Center for Disease Control and Prevention Shanxi, China); Wangqian Jia, Shaojing Dong, Wei Zhao, Qinghui Yang, Xiaoli Zhao, Lingbo Wang, Wei Huang, and Ailing Zhong (Wenxi County Center for Disease Control and Prevention, Shanxi, China); Baoxing Gao, Xiuzhen Li, Xia Zhang, Weina Feng, Lingling Qi, Bin Wei, Junmiao Zhu, and Qifeng Xu (Xia County Center for Disease Control and Prevention, Shanxi, China); and Jun Ji, Xia Zhang, Tingting Ma, Linna Li, Yanxia Li, and Qinghua Li (Jiang County Center for Disease Control and Prevention, Shanxi, China).

Disclosures
The authors have no financial conflicts of interest.

References
THE UPREGULATION OF LAG-3 IN HIV INFECTION


**Supplementary Figure 1.** (A) LAG-3 was significantly up-regulated in lymphocytes in SIV-1 infected non-human monkeys. LAG-3 is up-regulated on CD4⁺ (CD3⁺CD8⁻) and CD8⁺ T cells in SIV-infected non-human monkeys. Representative flow cytometric plots show LAG-3⁺ populations in CD4⁺ or CD8⁺ populations from representative chronically SIV-1-infected and uninfected subjects. The percentages of LAG-3⁺ cells in CD4⁺ and CD8⁺ T cell populations are grouped and compared between 9 uninfected (SIV⁻) and 25 SIV-1-infected(SIV⁺) subjects. Statistical analyses were performed using the Mann-Whitney test. (B) No significant differences in CD4⁺ T-cell counts and viral loads between LAG-3ʰⁱᵍʰ and LAG-3ˡᵒʷ groups. Forty patients in a cohort were stratified into two groups with either high or low LAG-3 expression and followed up for two years. Both viral loads (left panel) and CD4⁺ T cell counts (right panel) between these two groups did not reach significant differences at the starting point (p=0.07 for viral loads and p=0.76 for CD4 counts).
Supplementary Figure 2

(A) LAG-3 is largely expressed on activated CD4⁺ T cells. LAG-3 is primarily expressed on CD4⁺ TEMRA and TEM and less on TCM and T naïve. Representative flow cytometric plots show the distribution of LAG-3 or PD-1 positive CD4⁺ T cells among different T cell sub-populations as defined by CD45RA and CCR7 (upper panel). The population is overlaid onto density plots (black shading) of total CD4⁺ T cells. Percentages were calculated as the fraction of cells in each quadrant in total LAG-3 or PD-1 positive CD4⁺ T cells and compiled in bottom panel (n=53 for LAG-3 and n=28 for PD-1).

(B) LAG-3 is up-regulated after the stimulation of anti-CD3 and anti-CD28 antibodies. PBMCs from HIV-negative subjects are incubated for 4 or 7 days in the presence of purified anti-CD3 (1 ug/ml; clone UCHT1) and anti-CD28 (0.5ug/ml; clone CD28.2, BD Biosciences) antibodies. LAG-3 positive CD4⁺ or CD8⁺ T cells are monitored every day and the percentages are calculated as the number LAG-3 positive cells over the total number of CD4⁺ or CD8⁺ T cells. The kinetic expression of LAG-3 is exemplified in the upper panel and compiled in bottom panel.

(C) The up-regulation of LAG-3 in the early activation phase is largely accompanied by PD-1. The experiments were performed as described above, and the co-expression of LAG-3 and PD-1 was examined. The majority of LAG-3 T cells co-expressed with PD-1 during the early activation phase, and only a small fraction of T cells expressed LAG-3 alone and experienced different kinetics, with the LAG-3-expressing peak appearing on day one. Data are shown from three independent experiments with PBMCs derived from three HIV⁺ subjects.
Supplementary Figure 3

Supplementary Figure 3. The blockade of LAG-3 improves HIV-specific CD4+ T cell proliferation. Representative data show the expansion of CD4+ T cells in response to stimulations with SEB or of HIV-1 B Gag peptides alone or in the presence of IgG, LAG-3-Fc or anti-PD-L1 antibodies. Compiled data from 9 subjects were compared between IgG and LAG-3-Fc and between IgG and anti-PD-L1 antibodies. Statistical comparisons were conducted using wilcoxon signed rank test.